A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy
Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, single center, and a dose-escalating phase I study to determine
the maximal tolerated dose and the recommended dose of S-1 combined with
irinotecan/oxaliplatin in patients with unresectable or metastatic colorectal or gastric
carcinoma.